AI × Robotics × Biotech (MANBRIC) × Smart Cities Convergence: The 2026–2035 Supercycle of Capital Allocation

Technological revolutions are not equal as investment themes; they are equal as cost curves. Three curves are collapsing simultaneously in 2026-2030, the cost of AI inference, the cost of physical action (humanoid robotics and logistics), and the cost of biological reading/writing (sequencing, synthesis), and their intersection is creating the markets of the decade: instrumented smart cities, personalized healthcare, and physical labor automation. For the allocator, this is the first supercycle since the internet in which all three pillars reinforce one another.
Key data (framework). The financial leg of the supercycle is already measurable: AI has generated most of the growth in global technology capex since 2024; humanoid robotics moves in 2026-2027 from demonstration to pilot mass production (automotive and logistics factories); computational biotech (MANBRIC: the wave in which biology becomes a data science) reduces computational drug design costs by orders of magnitude; smart cities are deploying sensor infrastructure whose data themselves become assets, potentially tokenizable (infrastructure RWAs: tolls, data, distributed energy).
Analysis (quant lens). Three allocation rules for the supercycle:

• Buy cost curves, not narratives. For each theme: is unit cost falling by >20%/year? AI inference: yes. Robotic manipulation: yes (at the edge of the curve). Sequencing: yes, for 15 years. Smart city deployment: depends on public financing, selective by jurisdiction (Gulf, East Asia > Europe).
• Returns will come from the “picks and shovels”: compute, sensors, actuators, proprietary training data, and, this is the bridge to our studies 1-4, the financing and settlement infrastructure for these physical assets: a robot fleet or an urban sensor network is an asset with cash flows (subscriptions, pay-per-use), making it tokenizable, financeable through programmable private credit, and scoreable by an index. The technological supercycle and the RWA paradigm of study 1 converge: the rent economy finances the physical economy.
• Biotech/MANBRIC is the decade’s asymmetry: long duration, low correlation with macro cycles, venture-style convexity profile. In a portfolio: 5-10% of thematic allocation in vehicles with an appropriate duration, never in daily liquidity.
  Positioning. Long AI infrastructure (compute, energy, cooling), long “boring” robotics (logistics, inspection, agritech) ahead of consumer humanoids, long computational biotech platforms with proprietary data, selective smart cities (only jurisdictions with committed public financing and clarified data ownership). For the family office: a “cost curves” basket reviewed annually, with weights set by the unit deflation rate of each curve, a simple rule that beats narrative-driven stock picking.
  Risks. Valuation: the AI leg already prices in a great deal; Energy: data center power constraints are the real bottleneck; Biotech regulation: ethics governs the pace of commercialization; Geopolitics: robotics and biotech value chains are Sino-American, decoupling risk is permanent.
  Verdict. Structurally overweight, enter through cash-flow-generating infrastructure, finance innovation through programmable private credit rather than late-stage equity. The 21st-century rent economy finances the robots that produce it.